Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Breast 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Cholangiocarcinoma 1

Interventions

pembrolizumab 9Gemcitabine 5Cisplatin 5Nivolumab 3Drug Therapy 3budigalimab 2Paclitaxel 2Injections 2Docetaxel 2Carboplatin 2zenocutuzumab 1venetoclax 1tislelizumab 1spartalizumab 1seribantumab 1saracatinib 1rovalpituzumab tesirine 1pertuzumab 1pemigatinib 1niraparib 1nilotinib 1margetuximab 1lenvatinib 1futibatinib 1fludarabine 1entrectinib 1durvalumab 1crenigacestat 1cediranib 1bemarituzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × futibatinib × Breast × Clear all
NCT02052778 2025-03-27

A Study of TAS-120 in Patients With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1/2 Completed
407 enrolled 45 charts 1 FDA
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡